Investigational drug · Phase 3
Sintilimab
Also called: IBI308
Not approved by FDA. In 21 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
21
19 still active
All registered trials
728
Any phase or sponsor naming "Sintilimab"
First trial start
2021
Feb 7, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Sintilimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Hepatocellular Carcinoma
- Solid Tumor
- HCC - Hepatocellular Carcinoma
- Gastric Cancer
- Gastroesophageal Cancer (GC)
- Hepatocellular Carcinoma (HCC)
- Advanced Endometrial Cancer
- MSI-H
- Diffuse Large B-Cell Lymphoma
- Locally Advanced Rectal Cancer
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Stomach and esophageal cancer · Endometrial cancer · Lymphoma (non-Hodgkin) · Oncology · Hematology and blood cancers · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "Sintilimab" as an intervention, largest first.
- Multimodal AI for Predicting Response to Neoadjuvant Immunotherapy in Gastric Cancer (PRISM-GC)Recruiting
Qun ZhaoAcademic, hospital or other
NCT07401199 · 2,000 participants (planned) · Start Feb 5, 2026 · Primary completion Dec 30, 2027
Drug: Standard of Care PD-1 Inhibitors · For: Gastric Cancer (GC); Locally Advanced Gastric Cancer
Sites: Fuyang, China; Cangzhou, China; Hengshui, China · 9 sites in all
First Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
NCT06119347 · 1,581 participants · Start Jan 1, 2020 · Primary completion Jun 30, 2023
Drug: AntiVEGF; ICIs · For: AKI Incidence of Cancer Patients Receiving AntiVEGF or ICIs
Sites: Wenzhou, China
- The Effect of Serum Ferritin in irAERecruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT06702566 · 1,500 participants (planned) · Start Jul 4, 2024 · Primary completion Jul 16, 2026
Drug: PD-1 and PD-L1 inhibitor; Targeted drugs and 1 more · For: Immune-related Adverse Event; Malignant Solid Tumors; Acute Leukemia and 1 more
Sites: Tianjin, China
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Advanced HCCCompleted
Zhongda HospitalAcademic, hospital or other
NCT05332821 · 1,244 participants · Start Dec 28, 2022 · Primary completion Jul 30, 2023
Drug: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab · For: Hepatocellular Carcinoma
Sites: Nanjing, China; Shanghai, China
The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
NCT07852091 · 1,200 participants (planned) · Start Oct 10, 2023 · Primary completion Dec 31, 2026
Drug: Sintilimab/Envafolimab; ETV/TDF/TAF · For: Chronic Hepatitis B
Sites: Chongqing, China
- Anlotinib Plus Immune Checkpoint Inhibitors for Lung CancerPivotal-lookingRecruiting
Hunan Province Tumor HospitalAcademic, hospital or other
NCT04322617 · 1,200 participants (planned) · Start Mar 24, 2020 · Primary completion Mar 24, 2028
Drug: Anlotinib plus the same Immune Checkpoint Inhibitors.; Anlotinib plus the new Immune Checkpoint Inhibitors. and 1 more · For: Non-small Cell Lung Cancer
Sites: Changsha, China
- A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold RegionsActive, not recruiting
Harbin Medical UniversityAcademic, hospital or other
NCT07645209 · 1,000 participants (planned) · Start May 13, 2026 · Primary completion May 13, 2028
Drug: Immune Checkpoint Inhibitors · For: Liver Cancer
Sites: Harbin, China
- TACE in Combination With PD-1/PD-L1 Inhibitors and Molecular Target Therapies for Intermediate HCCCompleted
Zhongda HospitalAcademic, hospital or other
NCT05332496 · 941 participants · Start Dec 28, 2022 · Primary completion Jul 30, 2023
Drug: PD-1/PD-L1 inhibitors+VEGF-TKI/bevacizumab · For: Hepatocellular Carcinoma
Sites: Nanjing, China · 2 sites in all
Sun Yat-sen UniversityAcademic, hospital or other
NCT04680598 · 800 participants (planned) · Start Dec 25, 2020 · Primary completion Dec 31, 2023
Drug: ICI; Antiviral Prophylaxis · For: Hepatocellular Carcinoma
Sites: Guangzhou, China; Kaiping, China; Zhongshan, China · 4 sites in all
Cancer Institute and Hospital, Chinese Academy of Medical SciencesAcademic, hospital or other
NCT04423185 · 770 participants (planned) · Start Aug 15, 2020 · Primary completion Jul 1, 2026
Drug: Almonertinib 110 MG; Dacomitinib 45 MG and 9 more · For: Rare Tumor
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- Unexpected favorable response of stage IV gastric adenocarcinoma to sintilimab combined with chemotherapy: A case report.
Han J, Zhu Z, Huang L, et al. · Oncol Lett 2026
- Sequential combination of anti-PD-1 antibody and PEG-IFNα in chronic hepatitis B patients: correlates of HBsAg loss with enhanced T-cell responses.
Wang H, Zhang C, Li X, et al. · Emerg Microbes Infect 2026
- Sintilimabߛrelated cystitis/ureteritis in highߛgrade endometrial stromal sarcoma: A case report and structured literature review.
Yang S, Gao R, Li D, et al. · Hum Vaccin Immunother 2026
- Efficacy and safety of hepatic arterial infusion chemotherapy combined with palliative transarterial chemoembolization followed by targeted therapy and immunotherapy in patients with BCLC stage C hepatocellular carcinoma: Clinical trial protocol.
Fang Y, Zhang S · PLoS One 2026
- Cost-effectiveness analysis of sintilimab versus docetaxel as second-line therapy for squamous non-small cell lung cancer in China.
Li Y, Shi Y · Expert Rev Pharmacoecon Outcomes Res 2026
- CD14+ monocyte PD-L1 and VEGF-A reductions are associated with improved survival after sintilimab plus DOX in advanced gastric cancer.
Wang D, Zhou G · Int J Clin Pharmacol Ther 2026
Also in development for Hepatocellular Carcinoma
- IvonescimabAK112, SMT112Phase 349 trials
Akeso · Non-Small Cell Lung Cancer, Advanced Malignant Tumors, Advanced Solid Tumors
- CadonilimabAK104Phase 331 trials
Akeso · Hepatocellular Carcinoma, Gastric / Gastroesophageal Junction Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
- RilvegostomigAZD2936Phase 325 trials
AstraZeneca · Biliary Tract Cancer, Gastric Cancer, Non-small Cell Lung Cancer
- VolrustomigMEDI5752Phase 313 trials
AstraZeneca · Gastric Cancer, Non-small Cell Lung Cancer, Biliary Tract Cancer
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- FianlimabREGN3767Phase 311 trials
Regeneron · Melanoma, Non-small Cell Lung Cancer, Hepatocellular Carcinoma
- TiragolumabMTIG7192A, RO7092284Phase 311 trials
Roche (Genentech) · Hepatocellular Carcinoma, Rectal Neoplasms, Rectal Cancer
- ZG005Phase 311 trials
Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Advanced Solid Tumor, Lymphoma, Non-small Cell Lung Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.